Antioxidant therapy in the management of fluoroquinolone-associated disability

Robert Pietruszyński¹, Agnieszka Pietruszyńska-Reszetarska², Jan Sokal³, Marcin Domżalski⁴

¹Cardiology Outpatient Clinic, Military Medical Academy Memorial Teaching Hospital of the Medical University of Lodz – Central Veterans’ Hospital, Lodz, Poland
²Department of Internal Medicine and Cardiac Rehabilitation of the Medical University of Lodz, Lodz, Poland
³Maria Konopnicka Paediatric Centre, Central Teaching Hospital of the Medical University of Lodz, Lodz, Poland
⁴Department of Orthopaedics and Traumatology, Medical University of Lodz, Lodz, Poland

Submitted: 2 May 2018
Accepted: 4 October 2018

Arch Med Sci 2020; 16 (6): 1483–1486
DOI: https://doi.org/10.5114/aoms.2019.82717
Copyright © 2020 Termedia & Banach

Fluoroquinolone (FQ) antibiotics are often used in medical therapy, especially in the treatment of urinary tract infections (UTIs). Recently, serious adverse effects associated with their use have increasingly been reported. The US Food and Drug Administration (FDA) Adverse Event Reporting System (AERS) database includes 210,705 adverse events (and 2,991 fatalities) related to the use of FQs, as of January 2016 [1]. The most common adverse drug reactions (ADRs) associated with the FQs involve the gastrointestinal tract (nausea and diarrhoea), the central and peripheral nervous system (headache, dizziness, a “pins and needles” tingling or prickling sensation, confusion, hallucinations, and suicidal thoughts). Other potentially serious events involve the cardiovascular system (QT interval prolongation), musculoskeletal system (arthropathy, tendinopathy, tendon rupture, muscle weakness, joint pain and swelling) and glucose homeostasis dysregulation [2].

The FDA first added a black-box warning label for FQs in July 2008 regarding the increased risk of tendinitis and tendon rupture. In August 2013, the agency required new updates to the labels to describe the potential for irreversible peripheral neuropathy. In 2016 the FDA strengthened these warnings and emphasised the association of FQs with disabling and potentially permanent serious side effects, the risks of which generally outweigh the benefits in treatments for acute bacterial sinusitis, chronic bronchitis and uncomplicated urinary tract infections. In their most recent update of July 2018, the FDA required the drug labels to state that FQs may cause significant decreases in blood sugar and certain mental health side effects.

FQs are widely used in clinical practice despite the FDA’s recommendations restricting the use of these antibiotics. Unfortunately, this means the number of patients suffering from serious and chronic side effects of FQs is still growing. In addition, there is a lack of causative treatment at the current time. Disease-modifying and symptomatic treatment is complex, difficult and not standardized.

We present the case of a 43-year-old man, previously in good health, who experienced severe ADRs 5 days after completion of levofloxacin treatment, and was finally diagnosed with fluoroquinolone-associated
disability (FQAD). In 2015, for urological reasons, the patient underwent empirical, prolonged antibiotic therapy including a 24-day course of levofloxacin: 1500 mg (p.o.) daily for the first 3 days and 500 mg daily for next 21 days. Five days after treatment completion, the patient started to suffer from the first side effects. There were a number of different areas affected, including the central and peripheral nervous system (paraesthesia, speech and vision disorders, “pins and needles” sensation, chronic fatigue, anxiety, confusion, brain fog, memory loss and depression) and the musculoskeletal system (severe upper and lower limb pain, unusual neck pain, muscle weakness). Serious tendon, muscle and joint injuries were subsequently diagnosed. Additionally, gastrointestinal tract (uncommon food sensitivities), urinary tract and skin complaints were reported. During the next 3 years the patient underwent many specialist consultations in Poland, as well as in China and the USA.

A number of laboratory, functional and imaging tests were carried out. An electromyographic examination (EMG) in April 2015 revealed peripheral nerve demyelination. Magnetic resonance imaging (MRI) in September 2016 revealed bilateral degeneration of the forearm proximal tendons and degenerative changes of the neck muscles, with progression of these changes shown in the study of March 2018 (Figure 1). An earlier MRI study of April 2016 did not reveal any changes despite persistent clinical symptoms. Ultrasonography (USG) in September 2016 showed FQ-associated bilateral Achilles and forearm flexor tendinopathy. Bilateral partial rupture of the Achilles tendon was confirmed by MRI. An earlier USG examination of April 2016 did not reveal the described injuries despite the occurrence of constant pain. A number of other tests were also carried out, including the Organic Acids Test, which assess the intestinal bacterial flora and the level of mitochondrial markers of the Krebs cycle. Biochemical tests revealed a decreased level of neurotransmitters: dopamine, norepinephrine, epinephrine, glutamate, GABA and serotonin. Increased concentrations of vitamin B_{12}, in serum (1289 pg/ml) (norm: 197–771 pg/ml), folic acid (30.9 ng/ml) (norm: 3.1–17.5) and homocysteine (14.73 μmol/l) (norm: 5.00–13.90) were detected. Genetic tests performed in 2015 confirmed MTHFR A1298C, (MTHFR C677T polymorphism wasn’t detected) MAO A/R297R, and CYP3A4 gene polymorphisms. Other routine blood and urine tests were generally non-contributory.

Overall, following the levofloxacin treatment, the patient was repeatedly hospitalised in neurological and orthopaedic wards over a period of 3 years. Additionally, he was referred to specialists including a cardiologist, ophthalmologist, rheumatologist, neurosurgeon, urologist, acupuncture (pain management) specialist and physical therapist. The various multiple injuries and damage made him unable to work.

The patient was treated with medication aiming to reduce oxidative damage. Reduction of oxidative stress was achieved by increasing levels of endogenous and exogenous antioxidants and by stabilising mitochondrial energy production. He received intravenous antioxidant therapy: reduced L-glutathione (GSH), L-ascorbic acid, α-lipoic acid, ubiquinone (coenzyme Q10). The antioxidant therapy was combined with other compounds (e.g. magnesium sulphate) – essential in cellular metabolic processes as well as in

Figure 1. Cervical spine MRI: FSE T2 (A), TIW (B) sequences. Degenerative changes present at proximal attachment sites of the splenius muscles and longissimus capitis
Antioxidant therapy in the management of fluoroquinolone-associated disability

The genetic predisposition for increased risk of FQAD is not yet understood and further research is needed. A possible link between MTHR gene C677T and A1298C polymorphism associated with hyperhomocysteinaemia should be elucidated. In conclusion, the overuse of FQs and the growing number of reports of chronic adverse reactions (ADRs), including potential FQAD, are the main reasons to avoid FQs when other safer alternatives are available. Rigorous genotoxicity testing and further research must be continued and a “FQ risk assessment” should be a regulatory decision factor for whether to prescribe or not. Additional studies are necessary to determine which genetic factors underlie susceptibility and the genotypes predisposing to FQAD. There is an immediate need to perform preclinical studies and clinical research for the potential benefits and risks of high-dose antioxidant therapy, application of stem cells and other treatment strategies for FQAD.

Conflict of interest
The authors declare no conflict of interest.

References
1. US Food and Drug Administration. FDA Drug Safety Communication: FDA updates warnings for oral and injectable fluoroquinolone antibiotics due to disabling side effects. 2016. https://www.fda.gov/downloads/Drugs/DrugSafety/UCM515019.pdf
2. Stahlimann R, Lode HM. Risks associated with the therapeutic use of fluoroquinolones. Expert Opin Drug Saf 2013; 12: 497-505.
3. Michalak K, Sobolewska-Włodarczyk A, Włodarczyk M, Sobolewska I, Woźniak P, Sobolewski B. Treatment of the fluoroquinolone-associated disability: the pathobiological implications. Oxid Med Cell Longev 2017; 2017: 8023935.
4. Enzmann H, Wiemann C, Ahr HI, Schlüter G. Damage to mitochondrial DNA induced by the quinolone Bay y 3118 in embryonic turkey liver. Mutation Research 1999; 425: 213-24.
5. Golumb BA, Koslik HJ, Redd AJ. Fluoroquinolone-induced serious, persistent, multisystem adverse effects. BMJ Case Rep 2015; 2015: bcr2015209821.
6. Lawrence JW, Claire DC, Weissig V, Rowe TC. Delayed cytotoxicity and cleavage of mitochondrial DNA in ciprofloxacin-treated mammalian cells. Mol Pharmacol 1996; 50: 1178-88.
7. Hangas A, Asumets K, Kekäläinen N, et al. Ciprofloxacin impairs mitochondrial DNA replication initiation through inhibition of Topoisomerase 2. Nucleic Acids Res 2018; 46: 9625-36.
8. Kerkis C, Willoughby D. The antioxidant role of glutathione and N-acetyl-cysteine supplements and exercise-induced oxidative stress. J Int Soc Sports Nutr 2005; 2: 38-44.
9. Uivarosi V. Metal complexes of quinolone antibiotics and their applications: an update. Molecules 2013; 18: 11153-97.
10. Sæther N, Agarwal P. Effect of metal ions on some pharmacologically relevant interactions involving fluoroqui-
nolone antibiotics. Drug Metabol Drug Interact 2010; 25: 17-24.

11. Chui D, Cheng L, Tejani AM. Clinical equivalency of ciprofloxacin 750 mg enterally and 400 mg intravenously for patients receiving enteral feeding: systematic review. Can J Hosp Pharm 2009; 62: 127-34.

12. Mazidi M, Rezaie P, Banach M. Effect of magnesium supplements on serum C-reactive protein: a systematic review and meta-analysis. Arch Med Sci 2018; 14: 707-16.

13. Feng M, Yan L, Zhang X, et al. Fast removal of the antibiotic flumequine from aqueous solution by ozonation: influencing factors, reaction pathways, and toxicity evaluation. Sci Total Environ 2016; 541: 167-75.